TRCT
TLSIW icon

Tower Research Capital (TRC)’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Tower Research Capital (TRC)’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42
Closed -$46 – 5785
2024
Q4 		$46 Hold
42
– – ﹤0.01% 5554
2024
Q3 		$42 Hold
42
– – ﹤0.01% 5571
2024
Q2 		$70 Hold
42
– – ﹤0.01% 5522
2024
Q1 		$42 Hold
42
– – ﹤0.01% 5720
2023
Q4 		$50 Hold
42
– – ﹤0.01% 5769
2023
Q3 		$16 Buy
+42
New +$9 ﹤0.01% 5843

Other funds holding TLSIW

GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
ACM
Alpha Capital Management Austin, Texas $690M AUM 22.82% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.75B AUM 18.02% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tower Research Capital (TRC)'s TLSIW Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of TriSalus Life Sciences Warrant (TLSIW) in Q1 2025, closing a stake of 42 shares — an estimated $46 sold.

Tower Research Capital (TRC) first reported a position in TLSIW in Q3 2023 and held it in 6 quarters. The position peaked at $70 in Q2 2024. 6 funds tracked by Wall St. Rank hold TLSIW as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining TriSalus Life Sciences Warrant position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 42 TriSalus Life Sciences Warrant shares in Q1 2025, an estimated $46.
  • Tower Research Capital (TRC) first reported a position in TriSalus Life Sciences Warrant in Q3 2023 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s TriSalus Life Sciences Warrant position peaked at $70 in Q2 2024.
  • 6 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.